INTRODUCTION
T he short-term goal of lupus nephritis (LN) induction therapy is to achieve a clinical response, assessed mainly as a reduction in proteinuria and stabilization or improvement in kidney function. In human LN, the intrarenal molecular correlates of clinical response or nonresponse are not known, although such data are emerging in animal models of lupus. Understanding the kidney's molecular response to treatment may have therapeutic implications. For example, it is becoming increasingly clear that a clinical renal response may not reflect histologic resolution of kidney injury. 3 This raises the possibility that despite treatment and improvement of clinical signs of kidney injury, there may be ongoing activity of the intrarenal immune and inflammatory pathways that were engaged at the time of LN flare. Knowledge of these active pathways could facilitate maintenance therapy. Furthermore, patients who completely respond to treatment often develop chronic kidney damage, suggesting the activation of additional mechanisms of kidney injury, like fibrosis pathways, during therapy. 4 Such mechanisms, if known may be amenable to treatment, and this could attenuate the development of chronic kidney disease in lupus. For patients who do not respond to conventional immunosuppressive therapy, it is reasonable to assume that certain intrarenal immune and inflammatory pathways are still active, but without identifying these pathways the choice of an alternative treatment regimen remains uninformed.
To characterize the molecular correlates of clinical renal responses, we have examined intra-renal gene expression in serial biopsies from a well-phenotyped LN cohort. Transcript expression of genes relevant to immunity and inflammation were measured in kidney biopsy material taken at the time of LN flare and after completion of induction therapy in patients who responded completely to induction and patients who did not respond to induction. Differentially-expressed transcripts in LN biopsies relative to normal kidney were identified, and changes in transcript expression between responders and nonresponders during treatment were compared.
MATERIALS AND METHODS
Kidney biopsies. Kidney biopsies were done on 19 patients with proliferative (Class III or IV 6 V) LN between 2007 and 2011. The biopsies had been archived after all clinical testing was completed. Biopsy 1 (Bx1) was done to diagnose LN flare and biopsy 2 (Bx2) was done after LN induction therapy was completed. Patients were segregated by clinical response and only those who achieved a complete clinical response (n 5 5) or had a nonresponse (n 5 4) were included in the analysis. Ten patients achieved a partial clinical response and were not analyzed further in this study. Normal control kidney tissue was from archived kidney biopsies of living-donor kidneys (n 5 4), and was analyzed in parallel with the LN biopsies. The investigation of the kidney biopsies was approved by the Hospital Fernandez (Buenos Aires) ethics board and The Ohio State University institutional review board.
Treatment protocols and outcomes. All LN patients were treated with a tapering course of prednisone starting at 1 mg/kg/d and either mycophenolate mofetil (63% of patients) or intravenous cyclophosphamide (37% of patients). The induction period generally lasted 6 months. Clinical responses were assessed using achieved levels of serum creatinine concentration (SCr) and 24-hour urine protein when induction was finished. A complete clinical renal response (CR) was defined as having an improvement in proteinuria to ,0.5 g/d with normalization of SCr. A partial clinical renal response (PR) was defined as a reduction in proteinuria of .50% and to a level ,3 g/ d but .0.5 g/d, with stable or improved SCr. 5 A nonresponse (NR) was defined as less than 50% reduction in proteinuria or proteinuria that remained more than 3 g/d with stable or worsening Scr.
RNA extraction and analysis. The complete protocol for RNA isolation and analysis was previously described. 6 In brief, formalin-fixed and paraffinembedded kidney biopsy tissue blocks were sectioned. The sections were deparaffinized and whole tissue RNA was extracted from each biopsy using the RNeasy FFPE kit (Qiagen Valencia, CA). Transcript expression was analyzed from 250 ng of extracted RNA using the Nanostring ncounter platform and the AT A GLANCE COMMENTARY Parikh SV, et al.
Background
The diagnosis of lupus nephritis relies on clinical and histologic findings. Unfortunately, these findings do not inform treatment or determine prognosis. In addition, there are no markers to differentiate treatment responders from nonresponders.
Translational Significance
We evaluated the molecular profile of serial kidney biopsies in human LN to identify intrarenal transcripts that differentiate treatment responders from nonresponders. This has not been previously explored and provides insights into disease pathogenesis that cannot be appreciated by histology alone. We identify pathways that affect treatment response and may serve as novel therapeutic targets to improve response rates and facilitate personalized medicine in LN. Technologies, Seattle, WA).
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The human immunology panel consisted of 511 immune response genes, 6 positive control genes, and 6 negative control genes. A complete list of these genes can be found here http://www.nanostring.com/products/gene_expres sion_panels.
Statistical analysis. Descriptive statistics are presented as mean 6 standard deviation or as a percentage. For clinical variables, t-tests, ANOVA, or Wilcoxon rank sum tests were applied as appropriate. For categorical clinical variables, Fisher's exact test was used.
For Nanostring data, raw counts were normalized to the positive spike-in controls and then log2 transformed. To reduce technical bias, genes with an expression level below the mean plus 2xSD of the negative controls' expression for most samples were filtered out. Then quantile normalization method was employed to the remaining 468 genes across samples. Linear mixed effect models were used to identify differentially-expressed genes by taking into account the correlation between repeated measures before and after treatment. To improve the stability of variance estimation, variance smoothing methods and moderated t-tests were employed. 10 Since samples were profiled in 2 batches of different time points, batch effects were estimated in the model and adjusted for group comparisons as well. A total of 7 comparisons were performed based on 5 patients groups: Bx1 and Bx2 of CR patients and NR patients and normal kidney tissue as control. To determine differential expression, each group (Bx1 or Bx2 of CR or NR) was compared with normal control. To evaluate the change in transcript expression over time, Bx2 was compared with Bx1 within CR and within NR separately. The change in expression from Bx1 to Bx2 was also compared between the CR and NR groups. P values were adjusted by controlling the mean number of false positives at 5 out of 500 tests (ie, a 5 0.01). For any specific gene to be considered differentially expressed, at least a 2-fold difference in transcript level and a P-value ,0.01 must have been achieved.
Ingenuity Pathway Analysis (IPA, Qiagen) was used to evaluate the change in pathway expression with treatment in each group and to compare pathway expression after treatment between groups. Pathway analysis was done as described previously. 6 In brief, pathway analysis was conducted using less-stringent criteria than those used to identify differentially expressed genes. This was done to enrich the analysis for the targeted dataset. Transcripts that met inclusion criteria for pathway analysis had at least a 1.5-fold-change compared with normal controls and a P , 0.05. Using these parameters, 68 transcripts in CR and 189 transcripts in NR were included in the analysis.
RESULTS
The clinical, demographic, and pathologic characteristics of the LN kidney biopsy cohort are provided in Table I . All patients were White and Hispanic. The median time between Bx1 and Bx2 was 13 months, with a range of 6-37 months. The median time between Bx1 and Bx2 in the CR group was 13 months (6-37) and the median time between Bx1 and Bx2 in the NR group was 12.5 months (6-28). The clinical variables and followup time between biopsies for each patient are provided in Table II . Although clinical characteristics were generally similar between groups, NR had more proteinuria than CR. While not statistically significant, there were more first time LN flares in the CR group (60%) compared with the NR group (25%). The histologic activity and chronicity index were similar between the groups at flare and after treatment. After treatment, serum creatinine and proteinuria improved in CR but were worse in NR.
We approached the analysis of intrarenal transcript expression changes during LN induction therapy in 2 ways. First, to determine how well treatment reverses the altered pattern of gene expression that occurs in the kidney when LN flares, transcript expression profiles from Bx1 and Bx2 of CR were compared with transcript expression profiles from normal kidney tissue. Similarly, to determine whether the altered pattern of gene expression that occurs in the kidney when LN flares continues in patients who do not experience a clinical response, transcript expression profiles from Bx1 and Bx2 from NR were compared with transcript expression profiles from normal kidney tissue. Second, to develop a molecular signature of response, the changes in transcript expression from Bx1 to Bx2 in CR were directly compared with the changes in transcript expression from Bx1 to Bx2 in NR.
Transcript expression at flare and after treatment compared with normal kidney. At Bx1, 21 intrarenal transcripts were differentially expressed relative to control in patients who achieved a CR after induction compared with 45 differentially-expressed transcripts in those who had NR (Tables III and IV) . At Bx2, there were 28 differentially expressed transcripts in the CR group compared with 103 differentially expressed transcripts in the NR group (Tables III and IV) . For ease of comparison, in each column of Tables III  and IV , the bolded transcripts were differentially expressed in both CR and NR.
Several general patterns of gene expression changes during LN induction treatment became apparent. Despite complete clinical remission, 66% of the differentially expressed transcripts at flare remained differentially expressed at Bx2 compared with normal tissue. Most of these transcripts (86%) either did not change expression level or tended to shift their expression level toward normal (Table III) . In addition, 13 transcripts that were not differentially expressed at flare became so after treatment. Newly upregulated transcripts included, CX3CR1 (a chemokine receptor), LCK (lymphocyte-specific tyrosine kinase, a T cell signaling protein), and FN1 and TGFBI (genes for the profibrotic proteins fibronectin and transforming-growth factor beta-induced protein). Newly downregulated transcripts included, CISH, (a regulator of T cell receptor cytokine signaling), SOCS3 (STAT-induced cytokine signaling and suppressor of cytokine signaling-3), NKFBIA and NFKBIZ (NF-kB inhibitors), MME (a brush border neutral endopeptidase) and FKBP5 (an immunophilin).
In contrast, in the NR group 85% of the transcripts that had altered expression at flare continued to show altered expression after induction, and the expression level of 39% of these genes continued to increase relative to normal controls, whereas 55% did not change expression between Bx1 and Bx2 (Table IV) . Furthermore, an additional 66 transcripts became activated or suppressed at Bx2 (Table IV) . Six of these newly differentially expressed transcripts after treatment in NR overlapped with the 13 transcripts uniquely expressed after treatment in CR and included CX3CR1, LCK, IL8, NKBIA, TAL1, and FKBP5. In addition, 3 transcripts (TGFBI, IL6R, and MME) that were newly expressed in CR after treatment were already differentially expressed at flare in NR and remained so after treatment in NR.
Considering the gene products of the differentially expressed transcripts in CR and NR, a molecular definition of response and nonresponse begins to emerge. In this regard, the type I and II interferon, alternative complement, and T cell signaling pathways appear to discriminate between CR and NR during treatment (Fig 1) .
The interferon pathways. The intrarenal interferon signature was significantly upregulated at flare in CR and NR (Fig 1A and 1B) . Specifically, at Bx1, MX1, STAT1, IRF7, IFIH1, and IFITM1 levels were increased compared with control in CR. After treatment, MX1, IRF7, STAT1, and IFITM1 expression remained significantly elevated but their levels declined by 47%, 31%, 22%, and 20% respectively, relative to Bx1 (Fig 1A) . In NR, MX1, STAT1, and IRF7 were significantly upregulated at flare, but in contrast to CR their expression levels increased by 67%, 39%, and 34%, respectively, after treatment relative to Bx1 (Fig 1B) . Furthermore, several additional type I and II interferon-related genes became significantly upregulated after treatment in NR and include increased expression of IFITM1 (P 5 0.006), IRF8 (P 5 0.005), IFI16 (P 5 0.000), and STAT2 (P 5 0.000) ( Table IV) .
Because of the importance of interferon in SLE and LN, the interferon pathways in the kidneys were investigated in more detail by IPA upstream transcription analysis. This showed that the interferon-a, interferonb, and interferon-g pathways were upregulated at flare in CR, but after treatment only the interferon-b pathway remained upregulated (Fig 2A and 2B) . In contrast, in NR the interferon-a and interferon-b pathways were upregulated at flare and after treatment, and the interferon-g pathway became upregulated after treatment (Fig 2C and 2D) .
Complement pathways. Intrarenal alternative complement pathway-related genes were upregulated in CR and NR at flare, but changed discordantly with treatment (Fig 1C and 1D) . In NR, the expression of complement component 3 (C3) and complement factor D (CFD), key activators of the alternative pathway, increased 80% and 122% after treatment, respectively, whereas the expression of complement factor I (CFI), an important regulator of the alternative pathway, decreased by 44% (Fig 1C and 1D) . Compared with normal kidney, C3 expression was 5-fold higher (P 5 0.001), CFD expression was 8-fold higher (P 5 0.0002), and CFI expression was 3.5-fold lower (P 5 0.0001) after treatment in NR. In CR, CFD expression did increase after treatment, but did not reach significance, whereas C3 and CFI expression were similar to flare levels. T cell signaling pathways. Intrarenal expression of transcripts that facilitate T cell activation and proliferation increased at Bx2 in NR compared with normal controls (Fig 1E and 1F) . For example, the transcript for the protein tyrosine phosphatase receptor type C (PTPRC/CD45) was significantly increased at flare in NR (fold change [FC] 5 2.2, P 5 0.001), and expression further increased by 115% after treatment (FC 5 4.74, P 5 0.000) (Table IV) . T cell signaling and activation transcripts that became significantly upregulated in NR after treatment included LCP2 (FC 5 2.8, P 5 0.001), LCK (FC 5 2.8, P 5 0.0001), ZAP70 (FC 5 2.34, P 5 0.006), and CD5 (FC 5 2.6, P 5 0.009) (Fig 1E and 1F) .
Markers of leukocyte infiltration. The transcripts of several proinflammatory proteins associated with leukocyte infiltration were upregulated in NR compared with CR (Fig 3) . ITGAL and ITGB2 encode for the alpha and beta chains of the leukocyte integrin lymphocyte function-associated antigen 1 (LFA-1). LFA-1 facilitates adhesion of infiltrating leukocytes to renal endothelium. In NR, ITGAL (FC 5 3.7, P 5 0.0001) and ITGB2 (FC 5 3.5, P 5 0.000) levels were significantly increased at flare and post-treatment levels increased by 81% and 22% respectively, compared with flare levels (Table IV) . In addition, the alpha-integrin genes ITGAX (FC 5 3.1, P 5 0.0007) and ITGAM (FC 5 2.3, P 5 0.0007) were differentially upregulated after treatment in NR only.
In addition to integrin-mediated leukocyte infiltration, several chemokines were upregulated after induction therapy in NR. CCL19 increased 6-fold compared with normal (P 5 0.00006), and CXCL13 expression increased 2-fold relative to normal (P 5 0.008).
Colony-stimulating factor receptor transcripts CSF2RB and CSF3R are differentially upregulated after treatment in NR. CSF2RB expression was upregulated at flare compared with controls (FC 5 2.2, P 5 0.002) and its expression increased 86% relative to flare levels after treatment (P 5 0.01). Although it did not quite reach significance, after treatment, CSF3R expression increased 3-fold above controls levels in NR (P 5 0.01).
Comparison of transcript changes in response to treatment in responders and nonresponders. In a second approach to evaluate how gene expression is altered in the kidney during treatment, the change in transcript levels between Bx1 and Bx2 from CR were directly compared with changes between Bx1 and Bx2 from NR. Overall, 5 transcripts were different between CR and NR (Table V, Column 1). The origin of these differences is best understood by examining how each transcript changed from Bx1 to Bx2 in CR and NR separately (Table V, Columns 2 and 3). For example, C7, which encodes for complement component C7, a membrane anchor protein of the terminal complement pathway, was 4-fold higher in CR relative to NR with treatment (Table V, Column 1). This occurred because C7 levels remained stable in CR from Bx1 to Bx2 ( Table V , Column 2), but decreased by 72% from Bx1 to Bx2 in NR. NCAM1 expression fell between biopsies in NR but increased between biopsies in CR, accounting for a very large difference in NCAM1 expression between CR and NR. Several additional transcripts followed a similar pattern of expression after Network analysis of intrarenal interferon pathways in lupus nephritis. Network analysis was done to determine the extent of interferon pathway activation in lupus nephritis kidneys at flare and after treatment. In flares that ended in complete response, the interferon-a, b, and g pathways were predicted to be upregulated (A). After treatment, only the interferon-b pathway remained upregulated (B). In flares that ended in nonresponse, the interferona and b pathways were predicted to be upregulated (C). After treatment, the interferon-a, b, and g pathways were all predicted to be upregulated (D).
treatment. Most of these transcripts increased in expression in NR and stayed constant or decreased in CR (Fig 3) .
DISCUSSION
This is the first study to profile the expression of immune system genes in the kidneys of patients with LN before and after induction therapy, and associate changes in transcript expression with clinical responses to treatment. Several general observations emerged from this investigation. Most importantly, despite complete clinical remission after induction, intrarenal immune and inflammatory gene expression did not return to levels seen in normal kidneys, although most of these up-or downregulated (compared to normal) transcripts did decrease or increase expression toward normal, respectively. These findings are consistent with the lack of improvement in the activity index at Bx2 in clinical responders.
Patients who did not achieve a clinical response had many more immune genes activated or suppressed at flare than CR. In contrast to the changes observed in CR kidneys, in NR kidneys the expression of most of these genes tended to move further away from normal expression with treatment. In addition, during treatment, a handful of additional genes became up-or downregulated in responders, but many more became up-or downregulated in NR.
Overall, several conclusions may be drawn from these data. First, the results suggest that inflammatory and immune-injury pathways are highly dysregulated in the kidneys of patients at LN flare, and that standardof-care induction therapy is not adequate to normalize these pathways even in patients who respond well clinically. These data highlight the importance of maintenance immunosuppressive therapy after induction therapy has been completed for all LN patients. Furthermore, the extent of gene dysregulation is far greater in patients who do not respond to induction. While not statistically significant, the chronicity index at flare in NR was higher than CR and may account for some of the difference seen in transcript expression at flare between the 2 groups; however, both the activity and chronicity indices after treatment were similar between the 2 groups reinforcing the limitations of histology to recapitulate molecular changes. Thus, the highly dysregulated state of NR kidneys cannot be readily detected clinically at flare, and although proteinuria was greater in NR than CR, both groups presented with nephrotic-range proteinuria. Thus, molecular imaging of the kidney biopsy can provide clinically useful information not available by routine histology or clinical measurements.
Comparing the specific transcripts differentially expressed in CR and NR at flare, and how these transcripts changed with treatment identified several immune pathways that could be therapeutically targeted to improve clinical response in LN. These include the type 1 interferon pathway, the alternative complement pathway, and T-cell activation pathways.
Type I interferon genes were upregulated at flare in CR and NR. CR tended to downregulate interferon gene expression with treatment, but in NR, interferonassociated transcripts continued to increase. This suggests that anti-interferon therapy, now in clinical trial (NCT # NCT02547922), may be useful both in the initial treatment of LN and to potentially salvage patients who have not responded to induction therapy. Similarly, in both CR and NR, activators of the alternative complement pathway were upregulated in the kidney at flare, whereas regulators of the alternative complement pathway were downregulated. As with interferon-inducible transcripts, many of the complement genes tended to normalize expression with treatment in CR, but continued to be abnormally activated or suppressed in NR, suggesting that inhibitors of the alternative complement pathway, such as eculizumab or a C5a receptor antagonist, 11, 12 could be effective during the induction phase of LN treatment. Finally, several T cell activation transcripts appeared to be regulated differently in CR and NR kidneys. The most striking difference was the enhanced activation of these genes in NR after treatment. Specifically, transcripts important for T cell receptor recognition and engagement of antigen and kinases responsible for signal transduction and ultimately T cell activation were upregulated in NR only after treatment. 13 This enhanced T cell activation profile in NR may provide a mechanistic explanation for the apparent effectiveness of adding a calcineurin inhibitor to the standard of care therapy in increasing the short-term CR rates. 14 The specific transcripts upregulated in NR and CR kidneys relative to normal suggest that treatment resistance may be explained, in part, by activation of a program of tissue inflammation in NR kidneys that overwhelms standard-of-care therapy. For example, leukocyte chemotactic factors and their receptors are overexpressed in NR kidneys. CCL19 codes for macrophage-inflammatory protein beta-3, a T, B, and dendritic cell chemoattractant previously shown to be expressed in SLE. 15, 16 Transcripts for the B cell chemoattractant CXCL13, which is selective for B cells and follicular T cells were upregulated. CXCL13 has also previously been implicated in the pathogenesis of SLE in experimental models, 17, 18 and serum levels correlated with SLE and LN disease activity. 19 Once recruited to the kidney, the persistence and activation of inflammatory cells may be facilitated by leukocyte integrins, colony-stimulating factors and receptors, whose transcripts (ITGAL, ITGB2, ITGAM, IT-GAX, CSF2RB, CSF3R, FCAR/CD89, IL1RAP, PTPRC/ CD45) are upregulated in NR. Consistent with our observations, genome-wide association studies demonstrated that single nucleotide polymorphisms of ITGAM and ITGAX are strongly associated with SLE, 20 and FCAR has also been shown to be overexpressed in peripheral blood mononuclear cells of SLE patients.
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PTPRC is expressed on all leukocytes and PTPRC levels are not increased at flare or after treatment in CR, but were increased in NR at flare and continued to rise after treatment.
We also directly compared changes in transcript expression between Bx1 and Bx2 in CR and NR. Several additional transcript differences were seen by this analysis that were not apparent during the comparisons with normal kidneys. NCAM1, FCAR, and IL1-RAP are of particular interest. NCAM1 expression increased with treatment in responders only, whereas FCAR and IL1RAP expression increased in NR but decreased in CR with treatment.
NCAM1 is an adhesion molecule largely found in developing kidneys, but minimally expressed in adult kidneys. 22 NCAM1 expression increases when the adult kidney is damaged and may facilitate tubular regeneration. 23 It is also present in the early stages of fibrosis. 24 In LN, activation of NCAM1 may be important in renal healing by mediating repair of tubular epithelium and regulating the early stages of interstitial fibrosis. 23 In an experimental model of acute tubular necrosis, NCAM1 1 interstitial cells increased in the early phase of repair, and kidney injury was prolonged when these cells were eliminated. 23 In addition, NCAM1 1 interstitial cells increase in the early stages of interstitial fibrosis but are not present at late stages of fibrosis. 22 Increased tissue expression of NCAM1 after treatment in CR may signify ongoing repair that is not occurring in NR.
FCAR is the Fc receptor for IgA and encodes a transmembrane glycoprotein present on myeloid cells, including neutrophils, eosinophils, and macrophages, which activates several immune processes including endocytosis, phagocytosis, antibody-dependent cellmediated cytotoxicity, and release of inflammatory mediators. 25 Increased expression of FCAR may reflect infiltration of myeloid cells such as neutrophils and macrophages and suggests ongoing inflammation in non-responders.
IL1RAP forms a complex with the interleukin-1 receptor and activates proinflammatory cytokines through NF-kB. 26 This complex is responsible for IL-1-dependent activation of NF-kB and through NF-kB, proinflammatory cytokines are expressed in areas of tissue damage. Increased expression of IL1RAP after treatment in nonresponders is likely a response to ongoing kidney injury and reflects increased NF-kB-mediated cytokine expression in areas of active inflammation within the kidney.
This study has limitations. Sample size is small; however, these are clinical samples and the availability of serial biopsies for LN is limited. In addition, our data are similar to previous studies showing the molecular heterogeneity of LN. 1, 27 For example, a recent investigation of LN using microarray analysis of murine kidneys at different disease stages showed a significant increase in inflammatory gene expression at the onset of proteinuria that improved with treatment and returned to baseline levels at clinical remission. The LN cohort was Hispanic and from Argentina, and the controls were from Ohio. It is possible that some of the molecular heterogeneity of the kidney in LN is influenced by race/ethnicity. Therefore, these results may not be generally applicable to all LN patients. Finally, whole kidney cortex was used, and because the cortex represents mostly the tubulointerstitial space the data may not accurately reflect glomerular events.
In summary, molecular imaging of serial kidney biopsies from LN patients identifies several immune and inflammatory pathways that are dysregulated in the kidneys during active disease. Many of these pathways are consistent with what is known of the pathogenesis of kidney injury in LN. Importantly, molecular imaging shows how these pathways respond to standard-ofcare immunosuppression. It is clear that even with aggressive immunosuppression it is very difficult to turn off the dysregulated inflammatory and immune pathways active in LN kidneys. However, the data do suggest several therapeutic targets that could facilitate earlier and more complete disease resolution at the tissue level in clinical responders, and rescue clinical nonresponders. Some of these targets have not yet been tested or are just undergoing clinical trials in human LN. Molecular imaging of the kidney in LN provides insights into disease mechanisms that cannot be appreciated by histology alone. This approach to LN biomarker development may facilitate personalized medicine in LN and improve long-term kidney outcomes.
